

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office				Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
O INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)					
(37 CFR §1.98(b)) JAN 03 2006				Applicant: Wright, et al.	
				Filing Date: 2/2/2004	Group Art Unit: 1642

U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
BF	1.	3,859,277	1/7/75	Murakami, et al.	540	527	12/29/72
	2.	4,039,578	8/2/77	Suami	564	33	3/8/76
	3.	4,301,277	11/17/81	Acton, et al.	536	6.4	10/20/80
	4.	4,314,054	2/2/82	Acton, et al.	536	6.4	3/23/81
	5.	4,490,529	12/25/84	Rosowsky	544	260	9/6/83
	6.	4,494,547	1/22/85	Myers	604	20	3/30/81
	7.	4,579,827	4/1/86	Sakamoto, et al.	435	7.23	3/11/83
	8.	4,585,859	4/29/86	Mosher, et al.	536	6.4	4/9/84
	9.	4,639,512	1/27/87	Audibert, et al.	530	313	3/11/83
	10.	4,681,091	7/21/87	Picker, et al.	128	897	11/27/85
	11.	4,683,195	7/28/87	Mullis, et al.	435	6	2/7/86
	12.	4,683,202	7/28/87	Mullis	435	91	10/25/85
	13.	4,713,352	12/15/87	Bander, et al.	435	7.23	5/4/84
	14.	4,725,687	2/16/88	Piper, et al.	544	279	4/28/86
	15.	4,737,579	4/12/88	Hellstrom, et al.	530	388.85	7/23/86
	16.	4,753,894	6/28/88	Frankel, et al.	435	7.23	1/11/85
	17.	4,797,397	1/10/89	Suto, et al.	514	215	7/31/87
	18.	4,816,397	3/28/89	Boss, et al.	435	69.6	11/14/84
	19.	4,894,364	1/16/90	Greer	514	49	6/24/85
	20.	4,902,791	2/20/90	Roger, et al.	536	17.7	3/14/88
	21.	4,921,963	5/1/90	Skov, et al.	548	101	4/13/87
	22.	4,927,941	5/22/90	Kagiya, et al.	548	264.8	6/9/88
	23.	4,946,778	8/7/90	Ladner, et al.	435	69.6	1/19/89
	24.	4,950,480	8/21/90	Barber, et al.	424	178.1	5/5/87
	25.	5,004,606	4/2/91	Frincke, et al.	424	178.1	9/24/86
	26.	5,100,885	3/31/92	Abrams, et al.	514	184	8/1/89
	27.	5,147,652	9/15/92	Egyud	424	450	7/3/90
	28.	5,175,287	12/29/92	Lee, et al.	544	183	9/18/89
	29.	5,194,254	3/16/93	Barber, et al.	424	178.1	10/13/89
	30.	5,215,738	6/1/93	Lee, et al.	514	352	6/1/90
	31.	5,270,163	12/14/93	Gold, et al.	435	6	8/17/92
	32.	5,270,330	12/14/93	Suzuki, et al.	514	398	7/24/92
▼	33.	5,294,715	3/15/94	Papadopoulou-Rosenzweig, et al.	546	106	2/1/91
	34.	5,304,654	4/19/94	Kagiya, et al.	548	327.5	9/9/91
BF	35.	5,342,770	8/30/94	Yamasaki	435	178	5/11/93

Examiner: /Brandon Fetterolf/	Date Considered: 07/05/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR, §1.98(b))					Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
					Applicant: Wright, et al.	
					Filing Date: 2/2/2004	Group Art Unit: 1642

BF	36.	5,342,959	8/30/94	Beylin, et al.	548	327.5	8/5/93
	37.	5,442,043	8/15/95	Fukuta, et al.	530	303	11/29/93
	38.	5,457,183	10/10/95	Sessler, et al.	534	11	10/12/93
	39.	5,543,527	8/6/96	Beylin, et al.	548	110	5/18/95
	40.	5,545,806	8/13/96	Lonberg, et al.	800	6	12/16/92
	41.	5,569,825	10/29/96	Lonberg, et al.	800	18	12/17/91
	42.	5,571,845	11/5/96	Denny, et al.	514	619	5/26/94
	43.	5,574,142	11/12/96	Meyer, et al.	536	23.1	12/15/92
	44.	5,602,142	2/11/97	Papadopoulou-Rosenzweig, et al.	514	290	12/21/94
	45.	5,616,584	4/1/97	Lee, et al.	514	243	1/26/95
	46.	5,624,925	4/29/97	Lee, et al.	514	243	1/26/95
	47.	5,625,126	4/29/97	Lonberg, et al.	800	18	12/7/94
	48.	5,641,764	6/24/97	Martin, et al.	514	80	5/15/95
	49.	5,650,442	7/22/97	Mitchell, et al.	514	611	10/7/94
	50.	5,736,146	4/7/98	Cohen, et al.	424	197.11	2/22/95
	51.	5,760,029	6/2/98	Jadhav, et al.	514	210.16	3/13/97
	52.	6,071,532	6/6/00	Chaikof, et al.	424	450	10/15/96
▼	53.	6,110,687	8/29/00	Nilsen	435	6	6/18/99
BF	54.	6,409,990	6/25/02	Vera	424	9.35	5/12/00

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

	Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
						Yes	No
BF	55.	52089680	1977-07-27	JP	-		
	56.	53149985	1978-12-27	JP			
	57.	55059173	1980-05-02	JP			
	58.	57080396	1982-05-19	JP			
	59.	0142220	1985-05-22	EP	-		
	60.	61010511 A	1986-01-18	JP			
	61.	61167616 A	1986-07-29	JP			
	62.	62030768 A	1987-02-09	JP			
	63.	62039525 A	1987-02-20	JP			
	64.	62138427 A	1987-06-22	JP			
	65.	63099017 A	1988-04-30	JP			
	66.	63170375 A	1988-07-14	JP			
▼	67.	275966	1988-07-27	EP			
	68.	8806158	1988-08-25	WO			
BF	69.	0 287 317 A3	1988-10-19	EP			

Examiner:	/Brandon Fetterolf/	Date Considered:	07/05/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))					Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
					Applicant: Wright, et al.	
					Filing Date: 2/2/2004	Group Art Unit: 1642

BF	70.	63310873 A	1988-12-19	JP				
	71.	01139596 A	1989-06-01	JP				
	72.	8912690	1989-12-28	WO				
	73.	0185225	1990-03-01	EP				
	74.	02076861 A	1990-03-16	JP				
	75.	0434960	1991-07-03	EP				
	76.	2683529	1991-12-11	FR				
	77.	0296321	1992-09-23	EP				
	78.	0 513 351 B1	1992-11-19	EP				
	79.	07149737 A	1995-06-13	JP				
	80.	8280396	1996-10-29	JP				
BF	81.	1667600	2000-06-26	AU				
	82.	59-219300	1984-10-12	JP [abstract only]				
BF	83.	01-110675 A	1989-04-27	JP [abstract only]				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

BF	84.	Altschul et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, Nucleic Acids Res. 25(17):3389-3402
	85.	Arora et al. (1999) Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells, Cancer Res 59:183-188
	86.	Bhaskar et al. (2003) E-selectin up-regulation allows for targeted drug delivery in prostate cancer, Cancer Res 63:6387-6394
	87.	Carlson et al. (1985) Antigenic characterization of human hepatocellular carcinoma. Development of in vitro and in vivo immunoassays that use monoclonal antibodies, J Clin Invest 76(1):40-51
	88.	Chen et al. (1997) Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J Biol Chem. 1997 Feb 28;272(9):5974-82
	89.	Clackson et al., 1991, Making Antibody Fragments Using Phage Display Libraries Nature, 352:624-688
	90.	Dang et al. (1988) Identification of the human c-myc protein nuclear translocation signal, Mol Cell Biol. 8:4048-4054
	91.	Dang et al. (1989) Nuclear and nucleolar targeting sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat proteins, J Biol Chem 264:18019-18023
	92.	Daugherty et al. (1991) Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins, Nucl. Acids Res., 19:2471-2476
	93.	Davis et al. (1998) Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone, Blood 92:1184-1190
BF	94.	De Kruif et al. (1996) Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes, FEBS Lett., 399:232-236
BF	95.	Drabick et al. (1998) Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent, Antimicrob. Agents Chemother., 42:583-588

Examiner:	/Brandon Fetterolf/	Date Considered:	07/05/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)			
(37 CFR §1.98(b))		Applicant: Wright, et al.	
		Filing Date: 2/2/2004	Group Art Unit: 1642

BF	96.	Fawell et al. (1994) Tat-mediated delivery of heterologous proteins into cells, Proc Natl Acad Sci 91:664-668
	97.	Fridman et al. (2001) Cytochrome c depletion upon expression of Bcl-XS, J Biol Chem 276(6): 4205-10
	98.	Frohman et al. (1988) Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer, PNAS USA 85:8998
	99.	Gilliland et al. (1980) Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells, Proc. Nat'l Acad. Sci. USA 77:4539
	100.	Hara et al. (1997) Inhibition of interleukin 1bconverting enzyme family proteases reduces ischemic and excitotoxic neuronal damage, Proc Natl Acad Sci USA 94:2007-2012
	101.	Hazlehurst et al., 2001, Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells, Blood 96:1897-1903
	102.	von Heijne (1985) The leader peptides from bacteriorhodopsin and halorhodopsin are potential membrane-spanning amphipathic helices, J. Mol. Biol. 184: 99-105
	103.	Hellstrom et al. (1986) Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas, Proc. Natl. Acad. Sci. USA 83:7059-7063
	104.	Hood et al. (2002) Tumor regression by targeted gene delivery to the neovasculature, Science 296, 2404 -2407
	105.	Huse et al., (1989) Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda, Science, 246:1275-1281
	106.	Karaoglu et al. (1995) Functional characterization of Ost3p. Loss of the 34-kD subunit of the <i>Saccharomyces cerevisiae</i> oligosaccharyltransferase results in biased underglycosylation of acceptor substrates, J. Cell Biol. 130:567-577
	107.	Kawakami et al. (2002) Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy, Clin Cancer Res 8:3503-3511
	108.	Knoll et al. (2000) Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin thetaI1, Cancer Res 60:6089-6094
	109.	Koivunen et al. (1994) Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J. Cell Biol., 124: 373-380
	110.	Krolick et al. (1980) Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin, Proc. Nat'l Acad. Sci. USA 77:5419
	111.	Lavaissiere et al (1996) Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma, J Clin Invest 98(6):1313-23
	112.	Lechardeur, et al. (2000) Determinants of the nuclear localization of the heterodimeric DNA fragmentation factor (ICAD/CAD), J Cell Biol 150: 321-334
	113.	Lei et al. (1987) Characterization of the <i>Erwinia carotovora</i> pelB gene and its product pectate lyase. J. Bacteriol. 169:4379
	114.	Liang et al., 1996, Parallel Synthesis and Screening of a Solid Phase Carbohydrate Library, Science 274:1520-1522
▼	115.	Liu et al. (1996) Eradication of large colon tumor xenografts by targeted delivery of maytansinoids, Proc Natl Acad Sci 93:8618-8623
BF	116.	Loeber et al., 1991. Human NAD(+-)dependent mitochondrial malic enzyme. cDNA cloning, primary structure.

Examiner:	/Brandon Fetterolf/	Date Considered:	07/05/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))			
		Applicant: Wright, et al.	
		Filing Date: 2/2/2004	Group Art Unit: 1642

		and expression in <i>Escherichia coli</i> , <i>J. Biol. Chem.</i> 266:3016-3021
BF	117.	McCafferty et al., 1990, Phage antibodies: filamentous phage displaying antibody variable domains, <i>Nature</i> , 348:552-554
	118.	Ohara et al. (1989) One-Sided Polymerase Chain Reaction: The Amplification of cDNA, <i>PNAS USA</i> 86:5673-5677
	119.	Pai-Scherf et al. (1999) Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor, <i>Clin Cancer Res</i> 5:2311-2315
	120.	Pennington et al. (2001) IκB kinase-dependent chronic activation of NF-κB is necessary for p21 ^{WAF/Cip1} inhibition of differentiation-induced apoptosis of monocytes, <i>Mol Cell Biol</i> 21:1930-1941
	121.	Reed, 1997. Double identity for proteins of the Bcl-2 family, <i>Nature</i> 387(6635): 773-776
	122.	Roninson et al. (1986) Isolation of human mdr DNA sequences in multidrug-resistant KB carcinoma cells, <i>Proc Natl Acad Sci</i> 83:4538-4542
	123.	Ross et al. (2002) Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate, <i>Cancer Res</i> 62:2546-2553
	124.	Samejima et al. (1998) Transition from caspase-dependent to caspase-independent mechanisms at the onset of apoptotic execution, <i>J Cell Biol</i> 143:225-239
	125.	Shouval et al (1982) Selecting binding and complement-mediated lysis of human hepatoma cells (PLC/PRF/5) in culture by monoclonal antibodies to hepatitis B surface antigen, <i>Proc Natl Acad Sci, USA</i> 79:650-4
	126.	Suzuki et al. (2002) Possible existence of common internalization mechanisms among arginine-rich peptides, <i>J Biol Chem</i> 277:2437-2443
	127.	Tafani et al. (2000) Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial permeability transition, <i>Am. J. Pathol.</i> 156, 2111-2121
	128.	Tolcher et al. (1999) Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer, <i>J Clin Oncol</i> 17:478-484
	129.	Vivès et al., 1997 A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus, <i>J Biol Chem</i> 272:16010-16017
	130.	Vuist et al. (1994) Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein, <i>Blood</i> 83:899-906
	131.	Wright et al. (1994) Purification of a 24-kD protease from apoptotic tumor cells that activates DNA fragmentation, <i>J Exp Med.</i> 1994 Dec 1;180(6):2113-23
	132.	Wright et al. (1996) Biochemical pathways of apoptosis: nicotinamide adenine dinucleotide-deficient cells are resistant to tumor necrosis factor or ultraviolet light activation of the 24-kD apoptotic protease and DNA fragmentation. <i>J. Exp. Med.</i> 183: 463-471
▼	133.	Wright et al. (1997) Activation of CPP32-like proteases is not sufficient to trigger apoptosis: inhibition of apoptosis by agents that suppress activation of AP24, but not CPP32-like activity, <i>J Exp Med.</i> 1997 Oct 6;186(7):1107-17
BF	134.	Xu et al. (2000) Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2, <i>Clin Cancer Res</i> 6:3334-3341

Examiner:	/Brandon Fetterolf/	Date Considered:	07/05/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))		Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
		Applicant: Wright, et al.	
		Filing Date: 2/2/2004	Group Art Unit: 1642

BF	135.	Yang et al., 2001, Preparation and activity of conjugate of monoclonal antibody Hab18 against hepatoma F(ab') ² fragment and staphylococcal enterotoxin A., <i>World J Gastroenterol.</i> 7:216-221
	136.	Youle and Neville (1980) Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin. <i>Proc. Nat'l Acad. Sci. U.S.A.</i> 77:5483
	137.	Akamatsu et al. (1998) A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells. <i>Clin Cancer Res.</i> Nov;4(11):2825-32
	138.	Altschul, et al., 1990, Basic local alignment search tool. <i>J. Mol. Biol.</i> 215:403-10 [abstract only]
	139.	Balinsky et al., 1984, Enzyme activities in normal, dysplastic, and cancerous human breast tissues, <i>J. Natl. Cancer Inst.</i> 72:217-224 [abstract only]
	140.	Bernhard et al., 1983, Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain, <i>Cancer Res</i> 43:4420-4428 [abstract only]
	141.	Brody et al, 1999, The use of aptamers in large arrays for molecular diagnostics. <i>Mol Diagn</i> December;4(4):381-8 [abstract only]
	142.	Byers et al., 1989, Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer, <i>Cancer Res</i> 49:6153-6160 [abstract only]
	143.	Carloni et al., 1998, Knockout of alpha6 beta1-integrin expression reverses the transformed phenotype of hepatocarcinoma cells, <i>Gastroenterology</i> , Aug;115(2):433-42 [abstract only]
	144.	Chan et al, 2001, A humanized monoclonal antibody constructed from intronless expression vectors targets human hepatocellular carcinoma cells, <i>Biochem. Biophys. Res. Commun.</i> 284:157-167 [abstract only]
	145.	Chang et al, 1989, Serological analysis and biochemical characterization of monoclonal antibodies defining antigens of human hepatocellular carcinoma, <i>Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi.</i> 1989 Feb;22(1):1-20 [abstract only]
	146.	Chou, 1996, Nonidentity of the cDNA sequence of human breast cancer cell malic enzyme to that from the normal human cell, <i>J. Protein Chem.</i> 15:273-279 [abstract only]
	147.	Chou et al., 1997, Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation, <i>J Gastroenterol Hepatol</i> 12:569-575 [abstract only]
	148.	Chou et al., 1999, Solution structure of BID, an intracellular amplifier of apoptotic signaling, <i>Cell</i> , 96: 615-624
	149.	Coulas et al., 2003, The role of the Bcl-2 protein family in cancer, <i>Semin Cancer Biol</i> 13:115-123 [abstract only]
	150.	Davol et al., 1999, Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: characterizing and circumventing mechanisms of tumor resistance, <i>Prostate</i> 40:178-191 [abstract only]
	151.	Derossi et al., 1998, Trojan peptides: the penetratin system for intracellular delivery, <i>Trends Cell Biol</i> 8:84-87 [abstract only]
▼	152.	Di Lazzaro et al., 1994, Immunotoxins to the HER-2 oncogene product: functional and ultrastructural analysis of their cytotoxic activity, <i>Cancer Immunol Immunother</i> 39:318-324 [abstract only]
BF	153.	Ding et al., 1995, Synthesis and biological activity of oligosaccharide libraries. <i>Adv. Expt. Med. Biol.</i> 376:261-269 [abstract only]

Examiner:	/Brandon Fetterolf/	Date Considered:	07/05/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)			
(37 CFR §1.98(b))		Applicant: Wright, et al.	
		Filing Date: 2/2/2004	Group Art Unit: 1642

BF	154.	Drebin et al., 1988, Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo, <i>Oncogene</i> 2:387-394 [abstract only]
	155.	Dunk et al., 1987, In vitro and in vivo tumour localisation with a monoclonal antibody directed against a membrane antigen on the human hepatocellular carcinoma cell line PLC/PRF/5 <i>J Hepatol</i> 4(1):52-61 [abstract only]
	156.	Ecker and Crook, 1995, Combinatorial drug discovery: which methods will produce the greatest value, <i>Biotechnology (N Y)</i> , Apr;13(4):351-60 [abstract only]
	157.	Elliot et al., 1997, Intercellular trafficking and protein delivery by a herpesvirus structural protein. <i>Cell</i> 88:223-233 [abstract only]
	158.	Enari et al., 1998, A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor, ICAD, <i>Proc. Natl. Acad. Sci.</i> 95:9123-9128 [abstract only]
	159.	Ewend et al., 1996, Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models, <i>Cancer Research</i> 56(22):5217-5223 [abstract only]
	160.	Faouzi et al., 1999, Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an <i>in vivo</i> and <i>in vitro</i> study, <i>J Hepatol</i> 30:275-284 [abstract only]
	161.	Fitzgerald et al., 1989, Targeted toxin therapy for the treatment of cancer, <i>J. Nat'l Cancer Inst.</i> 81:1455 [abstract only]
	162.	Friede et al., 1994, Selective induction of protection against influenza virus infection in mice by a lipid-peptide conjugate delivered in liposomes, <i>Vaccine</i> , 12:791-797 [abstract only]
	163.	Fuhrer et al., 1991, Characterization of a membrane-associated glycoprotein (gp43) on human hepatocellular carcinomas by a monoclonal antibody, <i>Cancer Res.</i> 51:2158-2163 [abstract only]
	164.	Fukuda et al., 1988, A monoclonal antibody to the carbohydrate chain on human hepatocellular carcinoma-associated antigen which suppressed tumor growth in nude mice, <i>Cancer Immunol Immunother</i> 27(1):26-32 [abstract only]
	165.	Gho et al., 1999, Luteinizing hormone releasing hormone-RNase A conjugates specifically inhibit the proliferation of LHRH-receptor-positive human prostate and breast tumor cells, <i>Mol Cells</i> 9:31-36 [abstract only]
	166.	Gao et al., 2003, De novo identification of tumor-specific internalizing human antibody-receptor pairs by phage-display methods, <i>J Immunol Methods</i> 274:185-197 [abstract only]
	167.	Giantonio et al., 1997, Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer, <i>J Clin Oncol</i> 15:1994-2007 [abstract only]
	168.	Gilbert and Knox, 1997, Influence of Bcl-2 overexpression on Na ⁺ /K ⁽⁺⁾ -ATPase pump activity: correlation with radiation-induced programmed cell death. <i>J Cell Physiol</i> . Jun;171(3):299-304 [abstract only]
	169.	Goldstein et al., 1988, Expression of a multidrug resistance gene in human cancers, <i>J Natl Cancer Inst</i> 81:116-124 [abstract only]
BF	170.	Hiraiwa et al. (1990) Accumulation of highly acidic sulfated glycosphingolipids in human hepatocellular carcinoma defined by a series of monoclonal antibodies, <i>Cancer Res</i> 50(10):2917-28
BF	171.	Hiraiwa et al. (1990) Gangliosides and sialoglycoproteins carrying a rare blood group antigen determinant.

Examiner:	/Brandon Fetterolf/	Date Considered:	07/05/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR. §1.98(b))		Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
		Applicant: Wright, et al.	
		Filing Date: 2/2/2004	Group Art Unit: 1642

BF		Cad, associated with human cancers as detected by specific monoclonal antibodies, <i>Cancer Res</i> 50(17):5497-503
	172.	Hu et al., 1986, Monoclonal antibodies against antigens expressed on human hepatocellular carcinoma cells. <i>Hepatology</i> 6(6):1396-402 [abstract only]
	173.	Hu et al., 1999, Cloning and sequencing of variable region genes of HAb25 McAb against hepatocellular carcinoma. <i>Zhonghua Gan Zang Bing Za Zhi</i> 7(2):101-3 [abstract only]
	174.	Huang, 2000, Bcl-2 family proteins as targets for anticancer drug design, <i>Oncogene</i> 19(56): 6627-6631 [abstract only]
	175.	Hwang et al., 1984, Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen, <i>Cancer Res</i> 44:4578-4586 [abstract only]
	176.	Jaattela et al., 1999, Minireview Escaping cell death: Survival proteins in cancer, <i>Exp Cell Res</i> 248:30-43 [abstract only]
	177.	Jaskiewicz et al., 1993, Differential expression of extracellular matrix proteins and integrins in hepatocellular carcinoma and chronic liver disease, <i>Anticancer Res</i> 13:2229-2238 [abstract only]
	178.	Jones et al., 1986, Replacing the complementarity-determining regions in a human antibody with those from a mouse <i>Nature</i> , 321:522 [abstract only]
	179.	Joshi et al., 2002, IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein, <i>Br J Cancer</i> 86:285-291 [abstract only]
	180.	Kamps et al., 1996, Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity, <i>Biochim. Biophys. Acta</i> , 1278:183-190 [abstract only]
	181.	Kawahara et al., 1996 Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. <i>Cancer Res.</i> Dec 1;56(23):5330-3
	182.	Kawai and Hosaki, 1990, Clinical usefulness of malate dehydrogenase and its mitochondrial isoenzyme in comparison with aspartate aminotransferase and its mitochondrial isoenzyme in sera of patients with liver disease. <i>Clin. Biochem.</i> 23:327-334 [abstract only]
	183.	Kuwata et al., 1998, Antibody dependent cell-mediated cytotoxicity using hepatocellular carcinoma reactive monoclonal antibody, <i>J Gastroenterol Hepatol</i> Feb;13(2):137-44 [abstract only]
	184.	Kumagai et al., 1992, A new tumor-associated antigen useful for serodiagnosis of hepatocellular carcinoma, defined by monoclonal antibody KM-2, <i>Cancer Res</i> 52(18):4987-94 [abstract only]
	185.	Lee et al., 1999, Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds, <i>Bioconjug Chem</i> 10:973-81 [abstract only]
	186.	Li et al., 1998, Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis, <i>Cell</i> , 94: 491-501 [abstract only]
▼	187.	Lindenboim et al., 2000. Bcl-xS and Bax induce different apoptotic pathways in PC12 cells, <i>Oncogen</i> 19(14): 1783-1793 [abstract only]
BF	188.	Liu et al., 2001. Inhibition of the growth of hepatoma and hepatic metastasis by pingyangmycin conjugated

Examiner:	/Brandon Fetterolf/	Date Considered:	07/05/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))		Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
		Applicant: Wright, et al.	
		Filing Date: 2/2/2004	Group Art Unit: 1642

		with Fab' fragment of monoclonal antibody, Zhonghua Yi Xue Za Zhi 81:201-201 [abstract only]
BF	189.	Loh et al. 1989, Polymerase chain reaction with single-sided specificity: analysis of T cell receptor delta chain, Science 243:217-220 [abstract only]
	190.	Luo et al., 1998, Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors, Cell, 94: 481-490 [abstract only]
	191.	Markham et al., 1986, Primary hepatocellular carcinoma localised by a radiolabelled monoclonal antibody, J Hepatol 2(1):25-31 [abstract only]
	192.	Marshall et al., 1997, A biopolymer by any other name would bind as well: a comparison of the ligand-binding pockets of nucleic acids and proteins, Structure, 5: 729-734 [abstract only]
	193.	McDonnell et al., 1999, Solution structure of the proapoptotic molecule BID: a structural basis for apoptotic agonists and antagonists, Cell, 96:625-634 [abstract only]
	194.	Miura et al., 1993, Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the <i>C. elegans</i> cell death gene ced-3, Cell 75:653 [abstract only]
	195.	Moradpour et al., 1995, Specific targeting of human hepatocellular carcinoma cells by immunoliposomes in vitro, Hepatology 22(5):1527-37 [abstract only]
	196.	Morris et al., 2001, A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nature Biotech 19:1173-1176 [abstract only]
	197.	Motte et al. (1989) Characterization of a malignant phenotype-associated cell surface glycoprotein common to various human tumor cells and preferentially expressed on adenocarcinoma of the lung, Cancer Res 49(6): 1349-56 [abstract only]
	198.	Muchi and Yamamoto, 1983, Y Studies on mitochondrial and cytoplasmic malate dehydrogenase in childhood myelodysplastic syndrome, Blood 62:808-814 [abstract only]
	199.	Murray et al, 1993, The expression of cytochrome P-450, epoxide hydrolase, and glutathione S-transferase in hepatocellular carcinoma, Cancer 71:36-43 [abstract only]
	200.	Ng et al., 2000, Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response, Am J Clin Pathol 113:355-363 [abstract only]
	201.	Nishimura et al., 1987, Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen. Cancer Res. 1987 Feb 15;47(4):999-1005 [abstract only]
	202.	Ohzu et al, 1990, Multiplicity of newly established monoclonal antibodies against hepatocellular carcinomas, J Gastroenterol Hepatol 5(6):601-7 [abstract only]
	203.	Ozturk et al, 1989, Identification and characterization of a Mr 50,000 adrenal protein in human hepatocellular carcinoma, Cancer Res. 49(23): 6764-73 [abstract only]
	204.	Padlan, 1991, A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties, Molec. Immunol., 28:489 [abstract only]
▼	205.	Padlan, 1994, Anatomy of the antibody molecule, Molec. Immun., 31(3):169-217 [abstract only]
	206.	Pai et al., 1996, Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to <i>Pseudomonas</i> exotoxin, Nat Med 2:350-353 [abstract only]
BF	207.	Papsidero, 1985, Recent progress in the immunological monitoring of carcinomas using monoclonal antibodies, Semin. Surg. Oncol. 1(4):171-81 [abstract only]

Examiner:	/Brandon Fetterolf/	Date Considered:	07/05/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR §1.98(b))			
		Applicant: Wright, et al.	
		Filing Date: 2/2/2004	Group Art Unit: 1642

BF	208.	Park et al., 1994, MDR1 gene expression: Its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines, <i>J Natl Cancer Inst</i> 86:700-705 [abstract only]
	209.	Patriarca et al., 1993, Patterns of integrin common chain beta 1 and collagen IV immunoreactivity in hepatocellular carcinoma. Correlations with tumour growth rate, grade and size, <i>J Pathol</i> 171:5-11 [abstract only]
	210.	Penco et al., 2001, Identification of an import signal for, and the nuclear localization of, human lactoferrin, <i>Biotechnol Appl Biochem</i> 34:151-159 [abstract only]
	211.	Reff et al., 2001, A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications, <i>Crit Rev Oncol/Hematol</i> 40:25-35 [abstract only]
	212.	Seon et al., 1997, Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. <i>Clin Cancer Res</i> 3:1031-1044 [abstract only]
	213.	Shahinian et al., 1995, A novel strategy affords high-yield coupling of antibody Fab' fragments to liposomes, <i>Biochim Biophys Acta</i> , 1239:157-167 [abstract only]
	214.	Shao, 1986, Action of monoclonal antibody against a hepatocellular carcinoma cell line (PLC/PRF/5), <i>Zhonghua Zhong Liu Za Zhi</i> 8(4):259-61 [abstract only]
	215.	Shen et al., 1991, Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MDR1 gene expression, <i>J Cell Sci</i> 98:317-322 [abstract only]
	216.	Shimizu et al., 1997, Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases, <i>Leukemia</i> 11:1238-1244 [abstract only]
	217.	Shinohara et al., 2000, Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin, <i>Int J Oncol</i> 17:643-651 [abstract only]
	218.	Shouval et al., 1985, Human hepatoma-associated cell surface antigen: identification and characterization by means of monoclonal antibodies, <i>Hepatology</i> 5(3):347-56 [abstract only]
	219.	Siegall et al., 1994, In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats, <i>J Immunol</i> 152:2377-2384 [abstract only]
	220.	Sjogren et al., 1997, Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats, <i>Cancer Res</i> 57:4530-4536 [abstract only]
	221.	Song et al., 1998, Enhanced radioimmunotherapeutic efficacy of a monoclonal antibody cocktail against SMMC-7721 human hepatocellular carcinoma, <i>Cell Res.</i> 8:241-247 [abstract only]
	222.	Sordet et al., 1999, Selective inhibition of apoptosis by TPA-induced differentiation of U937 leukemic cells, <i>Cell Death Differ</i> 6:351-361 [abstract only]
▼	223.	Stein et al., 1991, A new murine monoclonal antibody against human hepatoma, <i>Hybridoma</i> 10:255-267 [abstract only]
BF	224.	Stemmer et al., 1995, Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides, <i>Gene</i> 16:49-53 [abstract only]

Examiner:	/Brandon Fetterolf/	Date Considered:	07/05/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR, §1.98(b))			
		Applicant: Wright, et al.	
		Filing Date: 2/2/2004	Group Art Unit: 1642

BF	225.	Stennicke and Salvesen, 1999, Caspases: preparation and characterization, Methods. Apr;17(4):313-9 [abstract only]
	226.	Takahashi et al, 1989, In vivo expression of two novel tumor associated antigens and their use in immunolocalization of human hepatocellular carcinoma, Hepatology 9(4):625-34 [abstract only]
	227.	Takahashi et al., 1988, In vivo localization of human colon adenocarcinoma by monoclonal antibody binding to a highly expressed cell surface antigen, Cancer Res 48(22):6573-9 [abstract only]
	228.	Takeuchi et al., 1999, Interferon-alpha modulates resistance to cisplatin in three human hepatoma cell lines, J Gastroenterol 34:351-358 [abstract only]
	229.	Tan, 1990, Production of monoclonal antibodies against human hepatocellular carcinoma by immunisation with a cell membrane preparation, Ann Acad. Med. Singapore 19:147-151 [abstract only]
	230.	Tanaka et al., 1996, Molecular cloning and mapping of a human cDNA for cytosolic malate dehydrogenase (MDH1) Genomics 32:128-130 [abstract only]
	231.	Tannock, 1996, Treatment of cancer with radiation and drugs, Journal of Clinical Oncology 14(12):3156-3174 [abstract only]
	232.	Tishler et al., 1992, Taxol: a novel radiation sensitizer, Int J Radiation Oncology and Biological Physics 22(3):613-617 [abstract only]
	233.	Torbenson et al., 2002, Hepatocellular carcinomas show abnormal expression of fibronectin protein, Mod Pathol 15:826-830 [abstract only]
	234.	Tsung et al, 1980, Derivation and characterization of a monoclonal hybridoma antibody specific for human alpha-fetoprotein. J Immunol Methods 39(4):363-8 [abstract only]
	235.	Venook et al., 2000, Hepatocellular carcinoma, Curr Treat Options Oncol. Dec;1(5):407-15 [abstract only]
	236.	Verheul et al., 1995, Monopalmitic acid-peptide conjugates induce cytotoxic T cell responses against malarial epitopes: importance of spacer amino acids. J. Immunol. Methods, 182:219-226 [abstract only]
	237.	Verhoeven et al., 1988, Reshaping human antibodies: Grafting an antilysozyme activity Science, 239:1534-1536 [abstract only]
	238.	Vitetta et al., 1987, Redesigning nature's poisons to create anti-tumor reagents, Science 238:1098 [abstract only]
	239.	Wagenknecht, K. et al. (1988) [Malate dehydrogenase isoenzymes in myocardial infarction] Kardiologia 28:55-57 [abstract only]
	240.	Wang et al, 1991, Trichosanthin-monoclonal antibody conjugate specifically cytotoxic to human hepatoma cells in vitro, Cancer Research 51:3353-3355
	241.	Wang et al, 1996, BID: a novel BH3 domain-only death agonist. Genes Dev. Nov 15;10(22):2859-69 [abstract only]
	242.	Wei et al., 2001, Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death, Science 292(5517): 624-626 [abstract only]
	243.	Weidmann et al, 1987, Human hepatocellular carcinoma: cross-reactive and idiotypic antigens associated with malignant transformation of epithelial cells, Hepatology 7(3):543-50 [abstract only]
BF	244.	Wisniewska and Lukasiuk, 1985, [Malate dehydrogenase and its isoenzymes in the peripheral blood leukocytes in progressive muscular dystrophy of the Duchenne type] Neurol. Neurochir. Pol. 19:318-322 [abstract only]

Examiner:	/Brandon Fetterolf/	Date Considered:	07/05/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

FORM PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR. §1.98(b))		Attorney Docket No.: ABSALUS-08602	Serial No.: 10/770,668
		Applicant: Wright, et al.	
		Filing Date: 2/2/2004	Group Art Unit: 1642

BF	245.	Wright et al., 1992, Selection of tumor cell variants for resistance to tumor necrosis factor also induces a form of pleiotropic drug resistance. <i>Cancer Immunol Immunother</i> 34:399-406 [abstract only]
	246.	Wright et al. (1998) Bcl-2-mediated resistance to apoptosis is associated with glutathione-induced inhibition of AP24 activation of nuclear DNA fragmentation. <i>Cancer Res.</i> 1998 Dec 1;58(23):5570-6
	247.	Xie et al., 1998, Characterization of a novel monoclonal antibody raised against human hepatocellular carcinoma. <i>Hybridoma</i> 17:437-444 [abstract only]
	248.	Yang et al., 1994, Sequence of light chain variable region gene of a monoclonal antibody to human hepatocarcinoma. <i>Zhonghua Zhong Liu Za Zhi</i> . Jul;16(4):263-5 [abstract only]
	249.	Yang et al., 1995, Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. <i>Cell</i> 80(2):285-291 [abstract only]
	250.	Yao et al., 2001, Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. <i>J Nucl Med</i> 42:1538-1544 [abstract only]
	251.	Yoon et al., 2000, Targeting a recombinant adenovirus vector to HCC cells using a bifunctional Fab-antibody conjugate. <i>Biochem Biophys Res Commun</i> 272(2):497-504 [abstract only]
	252.	York et al., 1996, The structures of arabinoxylglucans produced by solanaceous plants. <i>Carbohydr Res</i> . May 14;285:99-128 [abstract only]
	253.	Zeng et al., 1993, Radioimmunotherapy for unresectable hepatocellular carcinoma using 131I-Hepama-1 mAb: preliminary results. <i>J Cancer Res Clin Oncol</i> 119:257-7 [abstract only]
	254.	Zeng et al., 1994, Human anti-(murine Ig) antibody responses in patients with hepatocellular carcinoma receiving intrahepatic arterial 131I-labeled Hepama-1 mAb. Preliminary results and discussion. <i>Cancer Immunol Immunother</i> 39:332-336 [abstract only]
↓	255.	Zeng et al., 1998, Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of ¹³¹ I-anti-HCC mAb. Phase I/II clinical trials, <i>J Cancer Res Clin Oncol</i> 124:275-280 [abstract only]
BF	256.	Zhang, et al., 2002, Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. <i>Cancer</i> 95:896-906 [abstract only]

Examiner:	/Brandon Fetterolf/	Date Considered:	07/05/2006
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			